User profiles for Jodi B. Segal

Jodi B Segal

Professor of Medicine, Johns Hopkins University School of Medicine
Verified email at jhmi.edu
Cited by 21837

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

…, NM Maruthur, S Singh, JB Segal… - Annals of internal …, 2011 - acpjournals.org
Background: Given the increase in medications for type 2 diabetes mellitus, clinicians and
patients need information about their effectiveness and safety to make informed choices. …

Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis

…, Z Berger, Y Chu, E Iyoha, JB Segal… - Annals of internal …, 2016 - acpjournals.org
Background: Clinicians and patients need updated evidence on the comparative effectiveness
and safety of diabetes medications to make informed treatment choices. Purpose: To …

Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review

…, DR Nelson, MW Fried, JB Segal… - Annals of internal …, 2017 - acpjournals.org
Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …

Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence‐based review

JB Segal, WH Dzik… - …, 2005 - Wiley Online Library
BACKGROUND: The literature was systematically reviewed to determine whether a prolonged
prothrombin time or elevated international normalized ratio predicts bleeding during …

The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports

…, SK Vesely, BR Neas, JB Segal… - American journal of …, 2010 - Wiley Online Library
… Fogarty and Segal have recently published a concise … Also different from the review of
Fogarty and Segal, who … Similar to Fogarty and Segal, [1] we concluded that data from the …

Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

…, JP Weiner, JM Clark, JB Segal - JAMA internal …, 2013 - jamanetwork.com
Importance Acute pancreatitis has significant morbidity and mortality. Previous studies have
raised the possibility that glucagonlike peptide 1 (GLP-1)–based therapies, including a GLP-…

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

R Stasi, A Sarpatwari, JB Segal… - Blood, The Journal …, 2009 - ashpublications.org
Whether the eradication of Helicobacter pylori infection can increase the platelet count in
patients with immune thrombocytopenic purpura (ITP) is still a controversial issue. To provide …

Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American …

…, JE Rodnick, T Tobolic, B Ireland, JB Segal… - Annals of internal …, 2007 - acpjournals.org
This guideline summarizes the current approaches for the diagnosis of venous thromboembolism.
The importance of early diagnosis to prevent mortality and morbidity associated with …

Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

…, JE Rodnick, T Tobolic, B Ireland, JB Segal… - Annals of Internal …, 2007 - acpjournals.org
Venous thromboembolism is a common condition affecting 7.1 persons per 10 000 person-years
among community residents. Incidence rates for venous thromboembolism are higher …

[HTML][HTML] Prevalence of immune thrombocytopenia: analyses of administrative data

JB Segal, NR Powe - Journal of Thrombosis and Haemostasis, 2006 - Elsevier
Background: The prevalence of immune thrombocytopenic purpura (ITP) in the USA is
unknown. The paucity of data makes clinical trial design and resource allocation challenging. …